Who are GXHPC1's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Concentrated Bone Marrow Aspirate Injection, hUCB, ASC, MC, Stempeucel®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gxhpc1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

GXHPC1 — Competitive Intelligence Brief

GXHPC1 (GXHPC1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Stem cell therapy. Area: Regenerative Medicine.

phase 2 Stem cell therapy Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

GXHPC1 (GXHPC1) — Gwo Xi Stem Cell Applied Technology Co., Ltd.. GXHPC1 is a stem cell therapy that aims to repair damaged tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GXHPC1 TARGET	GXHPC1	Gwo Xi Stem Cell Applied Technology Co., Ltd.	phase 2	Stem cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Concentrated Bone Marrow Aspirate Injection	Concentrated Bone Marrow Aspirate Injection	Hospital for Special Surgery, New York	marketed	Autologous stem cell therapy
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
ASC	ASC	Anterogen Co., Ltd.	marketed	Autologous stem cell therapy
MC	MC	Aivita Biomedical, Inc.	marketed	Mesenchymal stem cell therapy
Stempeucel®	Stempeucel®	Cell Biopeutics Resources Sdn Bhd	marketed	Allogeneic mesenchymal stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Stem cell therapy class)

Ain Shams Maternity Hospital · 1 drug in this class
Gary A Levy, O. Ont. MD. FRCP AGAF · 1 drug in this class
Gwo Xi Stem Cell Applied Technology Co., Ltd. · 1 drug in this class
Manipal Acunova Ltd. · 1 drug in this class
Mesoblast, Inc. · 1 drug in this class
Nature Cell Co. Ltd. · 1 drug in this class
Tigenix S.A.U. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GXHPC1 — Competitive Intelligence Brief. https://druglandscape.com/ci/gxhpc1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab